These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16018938)

  • 81. Sociodemographic factors associated with postprostatectomy radiotherapy.
    Krupski TL; Kwan L; Litwin MS
    Prostate Cancer Prostatic Dis; 2005; 8(2):184-8. PubMed ID: 15809671
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Variation in prostate specific antigen (PSA) test ordering in primary care centers: tendencies 2002-2009.
    Lumbreras B; López-Garrigos M; Salinas M
    Clin Lab; 2012; 58(5-6):573-7. PubMed ID: 22783591
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study.
    Harlan LC; Potosky A; Gilliland FD; Hoffman R; Albertsen PC; Hamilton AS; Eley JW; Stanford JL; Stephenson RA
    J Natl Cancer Inst; 2001 Dec; 93(24):1864-71. PubMed ID: 11752011
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A stochastic model for prostate-specific antigen levels.
    Dayananda PW; Kemper JT; Shvartsman MM
    Math Biosci; 2004 Aug; 190(2):113-26. PubMed ID: 15234613
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men.
    Vollmer RT; Egawa S; Kuwao S; Baba S
    Cancer; 2002 Mar; 94(6):1692-8. PubMed ID: 11920530
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Prostate cancer conundrum.
    Thompson I
    Health News; 2000 Aug; 6(8):1-2. PubMed ID: 10948867
    [No Abstract]   [Full Text] [Related]  

  • 87. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer.
    Wu H; Sun L; Moul JW; Wu HY; McLeod DG; Amling C; Lance R; Kusuda L; Donahue T; Foley J; Chung A; Sexton W; Soderdahl D
    J Urol; 2004 Mar; 171(3):1111-6. PubMed ID: 14767282
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Advanced prostate cancer treatment guidelines: a global perspective; trends of hormone therapy in Japan.
    Akaza H
    BJU Int; 2004 Dec; 94 Suppl 3():5. PubMed ID: 15521883
    [No Abstract]   [Full Text] [Related]  

  • 89. Prostatic biopsies in selected men aged 75 years and older guide key clinical management decisions.
    Paterson AL; Sut MK; Khan AR; Sharma HK
    Int Urol Nephrol; 2013 Dec; 45(6):1539-44. PubMed ID: 23896941
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Watchful waiting, temporarily deferred therapy, or active surveillance?
    Parker C
    J Clin Oncol; 2005 Feb; 23(6):1322; author reply 1322-3. PubMed ID: 15718334
    [No Abstract]   [Full Text] [Related]  

  • 91. Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the 'Watchful Waiting' Study.
    Stratton MS; Reid ME; Schwartzberg G; Minter FE; Monroe BK; Alberts DS; Marshall JR; Ahmann FR
    Anticancer Drugs; 2003 Sep; 14(8):595-600. PubMed ID: 14501381
    [TBL] [Abstract][Full Text] [Related]  

  • 92. PSA doubling times.
    Newcombe H
    Lancet Oncol; 2000 Sep; 1(1):14-5. PubMed ID: 11905679
    [No Abstract]   [Full Text] [Related]  

  • 93. Comparison of the epidemiologic features and patterns of initial care for prostate cancer between public and private institutions: a survey by the Brazilian Society of Urology.
    Nardi AC; Reis RB; Zequi Sde C; Nardozza A
    Int Braz J Urol; 2012; 38(2):155-64; discussion 164-6. PubMed ID: 22555039
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Management of prostate cancer].
    Zilinberg K; Roosen A; Belka C; Ganswindt U; Stief CG
    MMW Fortschr Med; 2012 Jan; 154(1):47-50. PubMed ID: 22642004
    [No Abstract]   [Full Text] [Related]  

  • 95. Uncertainty in prostate cancer care: the physician's role in clearing the confusion.
    Wilt TJ
    JAMA; 2000 Jun; 283(24):3258-60. PubMed ID: 10866876
    [No Abstract]   [Full Text] [Related]  

  • 96. Comorbidity in patients with prostate cancer and its relevance to treatment choice.
    Post PN; Kil PJ; Hendrikx AJ; Janssen-Heijnen ML; Crommelin MA; Coebergh JW
    BJU Int; 1999 Oct; 84(6):652-6. PubMed ID: 10510110
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Re: Prostate-specific antigen testing among the elderly in community-based family medicine practices.
    Teichman PG
    J Am Board Fam Med; 2009; 22(6):707-8; author reply 708. PubMed ID: 19897701
    [No Abstract]   [Full Text] [Related]  

  • 98. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer.
    Krahn MD; Bremner KE; Asaria J; Alibhai SM; Nam R; Tomlinson G; Jewett MA; Warde P; Naglie G
    Urology; 2002 Aug; 60(2):258-63. PubMed ID: 12137823
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Urology.
    Chodak GW
    JAMA; 1994 Jun; 271(21):1717-8. PubMed ID: 8182870
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Initial treatment for prostate carcinoma in relation to comorbidity and symptoms.
    Hall HI; Satariano WA; Thompson T; Ragland KE; Van Den Eeden SK; Selvin S
    Cancer; 2002 Dec; 95(11):2308-15. PubMed ID: 12436436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.